The efficacy of dupilumab for the treatment of atopic dermatitis (AD) seen in clinical trials has been similarly observed in this real-life study. However, treatment with dupilumab is associated with a higher incidence of conjunctivitis and eosinophilia.
More patients with moderate-to-severe plaque psoriasis discontinued treatment with secukinumab despite receiving significantly fewer biologics prior to initiating this drug as compared with those treated with ixekizumab, a recent study has shown.
A complete response to dabrafenib and trametinib treatment in patients with unresectable or metastatic melanoma with BRAF V600E or V600K mutations leads to greater survival outcomes at 5 years, according to an analysis of data from the COMBI-d* and COMBI-v** trials.
Ustekinumab, delivered subcutaneously, is effective for patients with inflammatory bowel disease (IBD) receiving concomitant treatment for dermatological or rheumatological conditions, a recent study has found.
While exposure to UV light remains the top risk factor for skin cancer, other variables, such as smoking, immunosuppression and hypertension, also contribute to keratinocyte carcinoma, especially in nonwhite persons, a recent study has found.